Firms Sift Eye Study Data For Benefit From Lutein And Zeaxanthin

After the Age-Related Eye Disease Study found lutein, zeaxanthin and omega-3s do not slow age-related macular degeneration, supplement firms revisit the data and find lutein and zeaxanthin could slow the disease in deficient populations.

Dietary supplement firms are mining data for positive results after the second Age-Related Eye Disease Study showed that adding lutein, zeaxanthin and omega-3s does not improve on the original AREDS formulation’s benefit of slowing the progression of age-related macular degeneration or cataracts.

Vision health product makers Kemin Industries Inc.and ZeaVision LLC say secondary analysis of AREDS 2 data shows the carotenoids...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

More from North America